Understanding the Latest Financial Performance of REGN Stock


Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported a steep drop in sales in the most recent reporting quarter, not just year over year but also quarter over quarter. The major cause for the drop in income was a decrease in sales of the COVID-19 therapy medication.

Regeneron Pharmaceuticals Inc. (REGN) is, on the other hand, already striving to recoup income. The purchase of smaller developers is likely to be a top focus.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


Regeneron Pharmaceuticals Inc. (REGN) saw a 40% drop in sales in the first quarter of 2022 compared to the fourth quarter of 2021. The medicine REGEN-COV for the treatment of COVID-19 is the source of this dramatic drop in income. Due to its ineffectiveness against the omicron form, the FDA recently banned the use of this medication. As a result, sales of REGEN-COV are unlikely to recover anytime soon.

At the same time, Regeneron Pharmaceuticals is spending heavily in joint ventures, which boosted revenue by 63 percent year over year in the first quarter of 2022. Profit-sharing agreements provide the majority of the cash. REGN’s revenue may be bolstered in the near future as a result of beneficial agreements.

The company revealed earlier this month that it had acquired complete rights to the cancer medicine Libtayo, which it co-developed with Sanofi. Regeneron Pharmaceuticals Inc. (REGN) will record all sales and revenues related with the medication when the agreement closes in the third quarter of this year. Libtayo’s total international sales was $458.2 million last year.

REGN also recently completed the $250 million acquisition of Checkmate Pharmaceuticals, bolstering its oncology portfolio. The vidutolimod candidate, which is in phase II studies for a range of malignancies, including head and neck cancer, is Regeneron Pharmaceuticals’ major hope.

Regeneron Pharmaceuticals Inc. (REGN) has around $14 billion in cash on hand to conclude transactions. The firm intends to broaden its portfolio through deals in order to counteract sales declines caused by its COVID-19 medications. Only time will tell if this strategy is successful. However, the firm is in a transitional phase at this time, therefore investing in it is dangerous.


Please enter your comment!
Please enter your name here